Thrombolytic Articles & Analysis: Older
4 articles found
” The goal of the current study is to confirm the design of the device; it offers a purely mechanical approach to removing wall-to-wall clots, avoiding the use of thrombolytic drugs due to the associated bleeding risk, according to Vetex Medical CEO Mark Bruzzi. ...
The BEC is a pharmacomechanical device designed to enhance thrombolysis by increasing the exposure of thrombus to endogenous and exogenous thrombolytics. In Circulation: Cardiovascular Interventions, the investigators concluded, “In this early feasibility study of the BEC for intermediate - risk PE, there were no deaths or device-related adverse events and a significant ...
The recommended FDA dosage is up to 100 mg of systemic thrombolytics administered over a two-hour period for massive PE. However, up to 50% of patients who present with lower extremity DVT and who are treated with systemic anticoagulation alone develop post-thrombotic syndrome (PTS). ...
The aim of this study was to assess the value of the Cavity-to-Myocardium count ratio (CM ratio) calculated in the resting 99mTc-Sestamibi SPECT images to identify myocardial functioning status and recovery of myocardial function in patients with acute myocardial insult who have received thrombolytic therapy. The study demonstrates that the resting 99mTc-Sestamibi SPECT CM ratio ...